CPT code 20205 identifies a deep muscle biopsy, a surgical diagnostic procedure to obtain tissue from muscle located well below the fascia or beneath other muscles or bones. This procedure is clinically important for diagnosing inflammatory myopathies, muscular dystrophies, metabolic myopathies, and infectious or infiltrative processes that cannot be assessed by less invasive sampling. Nationally, deep muscle biopsy carries implications for procedural coding consistency, facility setting and resource use, and payer coverage policies for diagnostic surgical procedures.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context and typical sites of service, plus an overview of expected documentation elements and billing considerations tied to deep muscle biopsy procedures. The publication highlights common modifier usage and payer coverage patterns where available, and outlines benchmarking topics such as allowed services, place-of-service implications, and typical care pathways for surgical diagnostic biopsies.

This summary serves clinicians, coding professionals, and policy analysts seeking a national-level reference for CPT code 20205—covering what the code represents, why it matters for diagnosis and coverage decisions, and the practical topics to review when managing billing and utilization for deep muscle biopsy services.